Sign In
Buy INRLF
$2.74
+0.160 (+6.20%)
At Close: Jun 03, 2026
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
12:30pm, Wednesday, 26'th Nov 2025
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
06:37am, Wednesday, 26'th Nov 2025
Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
03:23pm, Thursday, 20'th Nov 2025
Valneva SE ( VALN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buh
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquir
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
12:02pm, Monday, 25'th Aug 2025
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US
10:29am, Monday, 25'th Aug 2025
Valneva SE VALN stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consisten
FDA suspends Valneva's chikungunya vaccine license in the U.S.
01:16am, Monday, 25'th Aug 2025
The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with immediate effect, the French drugmaker said on Monday.
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
03:20pm, Tuesday, 12'th Aug 2025
Valneva SE (NASDAQ:VALN ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Peter Buhler - Chief Financial Officer Th
Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults
08:18am, Friday, 11'th Jul 2025
The European Union's health regulator has lifted the temporary restriction on the use of French drugmaker Valneva's chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
10:29am, Monday, 09'th Jun 2025
UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above
Valneva SE (VALN) Q1 2025 Earnings Call Transcript
09:47am, Friday, 09'th May 2025
Valneva SE (NASDAQ:VALN ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President-Global Investor Relations Thomas Lingelbach - Chief Executive Offic
Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance
12:30am, Thursday, 08'th May 2025
Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva's main revenue vertical.
Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
08:40am, Wednesday, 07'th May 2025
The European Union's health regulator said on Wednesday it has begun a review of Valneva's chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally.
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
02:28pm, Monday, 14'th Apr 2025
The Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to Valneva SE's VALN single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in in
Valneva SE Shareholding Declaration - March 2025
11:45am, Thursday, 03'rd Apr 2025
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).
